Tone mix
Week by week 48 weeks
Share of Alcon Inc. Ordinary Shares's 199 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 3, 2026 · tone -92RxSight outlines $30M-$40M Alcon revenue recognition in 2026 while withdrawing full-year guidance (NASDAQ:RXST)-142
- Week of May 18, 2026 · tone -76Alcon Inc. (ALC) Sees Mixed Signals After Q1 Beat and Target Reduction-105
- Week of Aug 24, 2026 · tone -49SGA Exits Alcon (ALC) as Cataract Demand Slows and Competition Rises-104
- Week of Mar 16, 2026 · tone -81Alcon Ends Merger Agreement With LENSAR After FTC Opposition-95
- Week of Sep 29, 2025 · tone +96Alcon, STAAR Surgical Announce Expiration Of HSR Waiting Period+92
- Week of Oct 13, 2025 · tone -56ISS Recommends Staar Shareholders Vote Against Alcon Merger - Orange County Business Journal-80
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Alcon Inc. Ordinary Shares in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 7 | +50 |
| Last 30 sessions | 12 | +46 |
| Last 90 sessions | 46 | +53 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, October 23, 2026
2 headlines, average tone +99: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.bioxconomy.com · 1 outletAlcon bolsters retina portfolio with $550m Neurotech acquisitionPositive
- medcitynews.com · 1 outletAlcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma AcquisitionPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alcon bolsters retina portfolio with $550m Neurotech acquisition | www.bioxconomy.com | 1 | Positive |
| Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition | medcitynews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
2 headlines, average tone -50: 0 positive, 1 neutral and 1 negative. Showing all 2.
- vocm.com · 1 outletALC Profits Take a Hit as Players Walk Away from VLTs, Shift to 'Illegal' Online OperatorsNegative
- www.healio.com · 1 outletAlcon acquires Neurotech PharmaceuticalsNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| ALC Profits Take a Hit as Players Walk Away from VLTs, Shift to 'Illegal' Online Operators | vocm.com | 1 | Negative |
| Alcon acquires Neurotech Pharmaceuticals | www.healio.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
3 headlines, average tone +84: 3 positive, 0 neutral and 0 negative. Showing all 3.
- www.businesstoday.in · 1 outletAlcon plans new glaucoma treatment in India, targets premium eye care growthPositive
- www.finanznachrichten.de · 1 outletAlcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2Positive
- www.ocbj.com · 1 outletAlcon Acquires Neurotech Pharmaceuticals for $550M - Orange County Business JournalPositive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alcon plans new glaucoma treatment in India, targets premium eye care growth | www.businesstoday.in | 1 | Positive |
| Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 | www.finanznachrichten.de | 1 | Positive |
| Alcon Acquires Neurotech Pharmaceuticals for $550M - Orange County Business Journal | www.ocbj.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
2 headlines, average tone +99: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.finanzen.ch · 2 outletsAlcon Secures FDA Approval For BRYTLY OTC Redness Relief Eye DropsPositive
- www.rutlandherald.com · 1 outletFDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes | BusinessPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alcon Secures FDA Approval For BRYTLY OTC Redness Relief Eye Drops | www.finanzen.ch | 2 | Positive |
| FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes | Business | www.rutlandherald.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 7, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.c21media.net · 1 outletAlcon Media Group launches Alcon International Studios with Diego Piasek as president | NewsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Alcon Media Group launches Alcon International Studios with Diego Piasek as president | News | www.c21media.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Alcon Inc. Ordinary Shares, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.